skip to content


Issue No. 35 | August 22, 2008

News and Features

FDA: Atazanavir Label Updated

"The Reyataz (atazanavir) package insert has been updated to include important drug-drug interaction information regarding the administration of Reyataz with or without ritonavir and nevirapine, efavirenz, hormonal contraceptives, orally and parenterally administered midazolam, H2-receptor antagonists and drugs that are substrates of cytochrome P450 2C8."

For more information, read the FDA press release and the AIDSinfo atazanavir drug fact sheet.

Study: HAART Treatment Improves Syphilis Response Rates

"New research indicates that in patients co-infected with HIV, highly active antiretroviral therapy reduces syphilis serologic failure rates."

For more information, read the full story and study abstract.

Study Identifies HIV-Modulated Host Proteins That Affect Lipid Metabolism

"HIV replication alone (i.e., without any influence of antiviral drugs, or other human genetic factors), can induce novel cellular enzymes and proteins that are significantly associated with biologically relevant processes involved in lipid synthesis, transport and metabolism."

For more information, read the study abstract.

CDC Releases New Slide Set

"In this series of county-based dot-density maps, the data used are estimated AIDS cases by county, for the 50 US states, Washington D.C. and Puerto Rico, cumulative through 2005."

For more information, view and download the slide set.